title: Clinical doses of citalopram or reboxetine differentially modulate passive and active behaviors of female Wistar rats with high or low immobility time in the forced swimming test.
abstract: The sensitivity of immobility time (IT) to antidepressant-drugs differs in rats expressing high or low motor activity during the forced swimming test (FST). However, whether this heterogeneity is expressed after the administration of the most selective serotonin and norepinephrine reuptake inhibitors (SSRIs and SNRIs, respectively) is unknown. We compared the influence of either the SSRI citalopram or the SNRI reboxetine with the tricyclic antidepressant amitriptyline on two subgroups of female Wistar rats expressing high IT (HI; at or above the mean value) or low IT (LI; below the mean) during the initial 5 min of the first session of the FST. None of the tested drugs increased motor activity in the open field test. When vehicle was applied to either HI or LI rats, IT increased in the second session of the FST. This increment concurred with a simultaneous climbing time (CT) decrement. When amitriptyline (15 mg/kg) was tested the CT increased for both HI and LI rats. This increment was accompanied by an IT decrement in HI and LI rats. Reboxetine (0.16 or 1 mg/kg) precluded IT and CT changes in both HI and LI rats and produced a swimming time reduction. Citalopram (0.4, 1, and 3 mg/kg) essentially mimicked the influence of reboxetine on the IT and CT in LI rats, as well as in HI rats, but in the latter case only at 3 mg/kg. Yet, at the dose of 10 mg/kg citalopram lacked this effect in both subgroups. No differences were detected when the IT of LI rats was evaluated with citalopram (3 mg/kg) during estrus or diestrus stage. These results show that clinical doses of citalopram produced an antidepressant-like effect selectively in LI rats, while amitriptyline or reboxetine produced this effect in both LI and HI animals.
authors.affiliation: Departamento de Neurociencias, Universidad Autónoma de Yucatán, Av. Itzaes # 490, Mérida, Yucatán CP 97000, México. Electronic address: fserrano@uady.mx.
authors.forename: Ana Gisela
authors.initials: AG
authors.lastname: Flores-Serrano
authors.forename: María Leonor
authors.initials: ML
authors.lastname: Vila-Luna
authors.forename: Fernando José
authors.initials: FJ
authors.lastname: Álvarez-Cervera
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Heredia-López
authors.forename: José Luis
authors.initials: JL
authors.lastname: Góngora-Alfaro
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Pineda
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D015283:Citalopram / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D009025:Morpholines / Q000494:pharmacology*; D051381:Rats; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013550:Swimming
chemical_list: D018759:Adrenergic Uptake Inhibitors; D015283:Citalopram; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors
keywords: Antidepressant; Estrous cycle; Low/high activity; Rat; SNRI; SSRI